Skip to main content
. 2023 Jan 31;41(10):1830–1840. doi: 10.1200/JCO.22.02186

FIG 2.

FIG 2.

Disease-free survival subgroup analysis per investigator assessment (full analysis set; overall population). The subgroup analysis was performed using a Cox proportional hazards model including treatment, subgroup, and a treatment-by-subgroup interaction term. An HR < 1 favors osimertinib. EGFR, epidermal growth factor receptor; HR, hazard ratio.